Association of Focused Medication Review With Optimization of Psychotropic Drug Prescribing
A Systematic Review and Meta-analysis

Rory Sheehan, MSc; André Strydom, PhD; Emma Brown, BSc; Louise Marston, PhD; Angela Hassiotis, PhD

Abstract

IMPORTANCE Medication review has been proposed to achieve improved use of psychotropic drugs, but benefits have not been confirmed.

OBJECTIVE To synthesize evidence for focused psychotropic medication review in medication optimization.

DATA SOURCES Medline, PsycINFO, EMBASE, and CINAHL Plus were searched from inception to February 2018 using the index terms “drug utilization review” and “psychotropic drugs” and synonyms. Additional articles were retrieved using citation tracking and reference checking.

STUDY SELECTION Full-length, peer-reviewed articles that reported focused psychotropic medication review were included. Inclusion was determined against prespecified criteria and assessed independently.

DATA EXTRACTION AND SYNTHESIS Study quality was assessed using National Institutes for Health appraisal tools and informed a structured synthesis of results. Meta-analysis using a random effects model was conducted.

MAIN OUTCOMES AND MEASURES Change in the number or dosage of psychotropic medications, change in clinical parameters, change in patient-reported outcomes, and economic data were collected.

RESULTS A total of 26 studies met the inclusion criteria. Four studies were randomized clinical trials (n = 712 participants), while the remainder were before-after studies (n = 7844 participants). Most studies were conducted in elderly individuals, people with dementia, and adults with intellectual disability. Focused psychotropic medication review is a complex intervention; the professional(s) involved, target drug, degree of integration with usual care, and participant involvement varied greatly among the studies. Meta-analysis included 3 studies (n = 652 participants). Psychotropic medication review was associated with a reduction in prescribing of psychotropic drugs compared with control (pooled odds ratio, 0.24; 95% CI, 0.14-0.39) in elderly participants with cognitive impairment living in nursing homes. Before-after studies consistently reported a change in psychotropic drug prescribing after medication review, regardless of the population. Studies that reported the effects of psychotropic medication review on clinical outcomes failed to demonstrate benefit. Economic implications of focused psychotropic medication review were not adequately assessed. The quality of evidence is poor and studies are at risk of bias.

(continued)

Key Points

Question Does focused psychotropic medication review promote medication optimization?

Findings This systematic review and meta-analysis found that focused psychotropic medication review is associated with reduction in drug prescribing. Advantages for clinical and patient-important outcomes have not been shown.

Meaning More research using standardized medication review processes and outcome measures is needed before routine programs of focused psychotropic medication review can be recommended.

Open Access. This is an open access article distributed under the terms of the CC-BY License.
CONCLUSIONS AND RELEVANCE  Focused psychotropic medication review was associated with a reduction in prescribing of psychotropic drugs, but has not been shown to improve clinical outcomes or to provide economic benefit. More robust evidence is needed before programs of focused psychotropic medication review can be recommended as part of routine care for any patient group.

Introduction

The increasing worldwide use of psychotropic drugs and their application beyond licensed indications has attracted close scrutiny.1-3 At least 1 in 6 adults in the United States is prescribed psychotropic medication,4 and high levels of psychotropic drug use are demonstrated in several vulnerable groups, including elderly individuals,5 people with dementia,6 children and adolescents,7 and those with neurodevelopmental disorders, including autism8 and intellectual disability.9,10 Although undoubtedly of benefit to many individuals, psychotropic drugs are associated with significant adverse drug events that can affect quality of life and result in additional service costs.11,12 Spending on psychotropic drugs continues to grow13,14 and a high rate of nonadherence leads to significant waste.15

Medication optimization is a broad approach aimed at ensuring the safest and most effective use of medications.16 The concept has gained traction and has been applied to psychotropic drug prescribing, for example, in the Centers for Medicare & Medicaid Services’ recent efforts to reduce inappropriate antipsychotic prescribing in nursing homes.17

Medication optimization encompasses a range of strategies that may be used throughout the medication pathway, including educational interventions, formularies that identify drugs with the greatest perceived overall value, consensus guidelines to direct best practices, benchmarking of prescription rates, and decision aids developed to enable patients to take a more active role in treatment decisions based on their values and preferences. After a drug has been prescribed, optimization includes support for adherence and medication reconciliation. Medication review, a structured and critical evaluation of medication, might have a role in medication optimization, maximizing therapeutic efficacy, mitigating adverse events, and identifying opportunities for decreasing prescribing.18 In this systematic review we describe the content and delivery of focused psychotropic medication review and synthesize the evidence for its contribution to medication optimization.

Methods

A literature search was conducted in Medline, PsycINFO, EMBASE, and CINAHL Plus from inception to February 2018 to identify peer-reviewed original research articles that reported the effect of focused psychotropic medication review on medication optimization outcomes. Search terms included “drug utilization review” (and synonyms) combined with “psychotropic drugs” (and synonyms) (see eTable 1 in the Supplement for an example of full search strategy). Psychotropic drugs were defined in accordance with the World Health Organization Anatomical Therapeutic Chemical Classification System.19 Medication review was defined as a structured critical evaluation of medication with an aim to improve safety, efficacy, or cost-effectiveness. Optimization outcomes were intentionally broad. Any study design was included and there were no restrictions on population, setting, language, or date of publication. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. The protocol was registered prospectively with PROSPERO (registration No. CRD42017077244).

To limit potential confounding, studies were excluded if they reported a comprehensive medication review (including multiple classes of medication) or conducted a medication review as...
part of a multimodal intervention where the effect of medication review on reported outcomes could not be distinguished. Short reports, research letters, dissertations, and conference abstracts were not included but prompted a search for full-length articles. Reference lists of included studies and previously published reviews in the field were extensively hand searched to find articles not identified in the database search. The citations of included articles were identified using Google Scholar and considered for relevance.

After exclusion of duplicate records, the titles of all articles were screened by one of us (R.S.), and a randomly selected sample was independently reviewed by another of us (E.B.). They independently reviewed abstracts of remaining studies (and later selected full text) against inclusion and exclusion criteria, with any discrepancies resolved by consensus or discussion with a third member of the research team.

Study quality was rated independently by 2 of us (R.S. and E.B.) using the relevant quality checklist published by the National Institutes of Health along with a descriptive evaluation of the limitations of each article. Studies received an overall grading of poor, fair, or good quality based on the proportion of applicable checklist items that were met (poor, <30% of items; fair, 30%-60%; good, >60%). Results of the quality appraisal were used to inform a structured evidence synthesis, with higher-quality studies given precedence.

Data were extracted from studies and used to populate summary tables. Type of medication review was classified according to the Task Force on Medicines Partnership and the National Collaborative Medicines Management Services Program (level 1, prescription review; level 2, treatment review; level 3, clinical medication review). Outcomes were grouped according to theme, allowing comparison between different studies. Measures of psychotropic drug optimization could include changes in medication-related variables, clinical efficacy or adverse drug events, participant-reported outcomes, or economic evaluations. Additional data were sought by contacting authors of included studies, where indicated.

Results were summarized narratively. Numerical data were extracted and, where comparable, means and 95% CIs were calculated around summary statistics. Odds ratios for comparable outcomes reported in randomized clinical trials (RCTs) were entered into a meta-analysis using the metan command in Stata, version 14 and using a random-effects model. The $I^2$ statistic was used to estimate statistical heterogeneity between studies.

Results

The search yielded a total of 9485 articles, of which 27 met inclusion criteria (Figure 1). The results of 1 study were reported in 2 articles and the remaining 22 were before-after study designs. Studies were conducted in North America (15 studies), Europe (10 studies) and Australasia (1 study). A total of 19 studies were conducted in institutional settings and reported psychotropic medication review of people with intellectual disability (9 studies; 1054 participants) or those with dementia (6 studies; 3664 participants). Meta-analysis included 3 studies (n = 652 participants).

Details of included studies are in eTable 2 in the Supplement. When assessed against objective criteria, most research was at medium to high risk of bias. Key methodological problems encountered across studies were single group design, reporting bias, lack of measures of implementation fidelity, lack of objective and validated outcome measures, short follow-up times, and limited (or absent) statistical analysis. Several studies made claims that were not supported by the findings.

Content and Delivery of Psychotropic Medication Review

The focused psychotropic medication reviews fell into 3 major categories. The first was one-off medication review, usually undertaken by a single professional and including a single class of psychotropic drug. The second model was a longitudinal program of regular medication
review, often by a multidisciplinary team who reviewed the participant’s psychotropic drug regimen in a series of meetings.\textsuperscript{26-37,39} The third type of focused psychotropic medication review was 2-stage, in which those at high risk of suboptimal drug therapy were identified using a rule applied to the electronic patient record and then directed to clinician medication review.\textsuperscript{46-49} Within this categorization, the configuration of focused psychotropic medication review varied considerably from remote review by a third party to detailed medication review with access to the patient’s full clinical notes and the patient’s direct input to the process (Table 1).\textsuperscript{18,23-49} Medication reviews were most often organized according to local protocols, but specific conduct of the medication review was commonly not reported.

Studies reported review of antipsychotic drugs (9 studies),\textsuperscript{23,25,29,31,32,37,38,40,41} sedatives and hypnotics (2 studies),\textsuperscript{43,49} antidepressants (2 studies),\textsuperscript{44,45} or several psychotropic drug classes concomitantly (13 studies).\textsuperscript{26-28,30,33-36,39,42,46-48} A range of medical and other health professionals were involved in medication reviews, with the most consistent representation being by clinical pharmacists. A minority of reviews incorporated involvement of the patient or family or advocate.

Several studies reported standardized methods of data collection that were used to inform medication review, although few used validated instruments to measure clinical variables. Most focused psychotropic medication reviews relied on implicit decision making and clinician judgment, rather than explicit measures of drug appropriateness and best practice guidelines.
| Source | One-Off Medication Reviews | Meds | Professionals Involved | Review Delivery | Guideline and Instruments Used | Review Level* |
|--------|-----------------------------|------|------------------------|----------------|-------------------------------|---------------|
| Ballard et al, 2016, and Ballard et al, 2017 | 277 People with dementia, nursing home | Antipsychotic drugs | Physician | NR | General practitioner or psychiatrist performed antipsychotic review using clinical guidelines to determine appropriateness and direct withdrawal attempts | 1 |
| Moncrieff et al, 2016 | 60 People with severe mental illness, community | Antipsychotic drugs | Physician and care coordinator (nurse, social worker, occupational therapist) | Yes: patient | Patients used a medication review tool with their care coordinator prior to a psychiatrist appointment; the tool incorporated perceived benefits and disadvantages of antipsychotic drugs and desired changes, which could be discussed with the prescriber | 2 |
| Gallimore et al, 2016 | 144 Children and adults with mental illness, community | Psychotropic drugs | Pharmacist | No | Pharmacist reviewed medication record and, where indicated, made recommendations (dose reduction, drug discontinuation, reevaluation of symptoms, or switch to alternative drug) to the prescriber | 3 |
| Prentice and Wright, 2014 | 3165 Older adults, nursing home | Antipsychotic drugs | Pharmacist, care staff, physician | No | Pharmacist reviewed symptoms, adverse effects, and medication-related information, discussed with care staff, and made recommendations to physician | 1 |
| Gemelli et al, 2016 | 34 Older adults, nursing home | Sedative and hypnotic drugs | Pharmacist, care staff, physician | No | Pharmacist reviewed medication record and, where indicated, made recommendations (dose reduction, drug discontinuation, reevaluation of symptoms, or switch to alternative drug) to the prescriber | 2 |
| Child et al, 2016 | 2849 Adults, community | Antidepressant drugs | Pharmacist, care staff | Yes: patient and family | Physician completed face-to-face medication review | 3 |
| Johnson et al, 2015 | 41 Elderly, nursing home | Antipsychotic drugs | Nurse | Yes: Patient and family | Nurse or prescriber completed face-to-face medication review including discussion of adverse effects and unmet needs, and medication adherence | 3 |

*Review Level: 1 (low), 2 (moderate), 3 (high)
### Table 1. Focused Psychotropic Medication Review—Summary of Content and Delivery (continued)

| Source                  | Participants, Setting                        | Psychotropic Drugs Reviewed | Professionals Involved                                                                 | Patient or Patient Representative Involvement | Review Delivery                                                                 | Guidelines and Instruments Used                                                                 | Review Level |
|-------------------------|---------------------------------------------|----------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|--------------|
| Patterson et al, 2010   | 334 Elderly individuals, nursing home       | Psychotropic drugs         | Pharmacist, physician                                                                  | Yes: patient and family                       | Monthly pharmacists reviewed patient records and interviewed patients and family to identify drug-related problems and used an algorithm to identify potentially inappropriate psychotropic drug prescribing; pharmacist recommendations discussed with physician and drug decisions made | Fleetwood algorithm for appropriateness of psychotropic drug prescription                           | 3            |
| Bach et al, 2017        | 20 People with dementia, nursing home       | Antipsychotic drugs        | Pharmacist                                                                              | No                                            | Monthly pharmacist screened medication charts against criteria for appropriate antipsychotic use and made recommendations to the physician | Antipsychotic Use Survey Tool was used to determine appropriate and inappropriate antipsychotic prescribing | 1            |
| Morrison, 2009          | 22 Older adults, nursing home                | Antipsychotic drugs        | General practitioner                                                                   | NR                                            | General practitioner completed structured review of antipsychotic prescribing supported by a checklist based on NICE guidance every 6 mo | No formal guidelines or standard instruments used in this medication review                  | CD           |
| Dahl et al, 2008        | 110 People with dementia, long-term care    | Psychotropic drugs         | Nurse, social worker, pharmacist, physician                                            | Yes: family                                   | Multidisciplinary team gather information using a standard assessment form covering symptoms, behavior, adverse effects, and patient and family concerns every 6 mo; followed by a multidisciplinary team meeting where recommendations to optimize prescribing are agreed and sent to the prescriber | Psychotropic Assessment Tool                                                                 | 3            |
| Branford, 1996          | 198 People with intellectual disability, institution | Antipsychotic drugs        | Nurse, psychiatrist, pharmacist                                                         | No                                            | Regular multidisciplinary meeting to review diagnosis, behavior, and medication prescribing; prescribing decisions made by consensus | Aberrant Behavior Checklist, Psychopathology Instrument for Mentally Retarded Adults, Reiss screen | 2            |
| Bisconer et al, 1995    | 80 People with intellectual disability, institution | Psychotropic drugs         | Physician, pharmacist, psychologist, nurse, other professional staff, lay participants | No                                            | Multidisciplinary meetings to discuss presentation, drug adverse effects, and broader treatment plan every 6 mo; changes to prescribing made by consensus | Standard report (no validated instruments)                                                    | 2            |
| Jauernig et al, 1995    | 25 People with intellectual disability, institution | Psychotropic drugs         | Pharmacist, physician, physician, care staff, clinical manager                          | No                                            | Multidisciplinary meetings every 2 mo to discuss presentation and progress, review data collected on standardized forms, and agree drug recommendations to be made to treating physician | Behavior monitoring record forms, Aberrant Behavior Checklist, adverse effect monitoring checklist | 2            |
| Glaser et al, 1986      | 28 People with intellectual disability, institution | Antipsychotic drugs        | Physician, nurse, pharmacist, psychologist, care staff, administrator                  | No                                            | Monthly multidisciplinary team review including indication for medication, symptoms, alternative treatments, and medication response; recommendations made | No formal guidelines or standard instruments used in this medication review                  | 2            |
| Marcoux, 1985           | 255 People with intellectual disability, institution | Psychotropic drugs         | Physician, psychologist, nurse, pharmacist                                             | No                                            | Multidisciplinary meetings every 3 mo to review symptoms, adverse effects, and other information and inform medication decisions | Standard data sheets completed                                                               | 2            |

(continued)
### Table 1. Focused Psychotropic Medication Review—Summary of Content and Delivery (continued)

| Source | Participants, Setting | Psychotropic Drugs Reviewed | Professionals Involved | Patient or Patient Representative Involvement | Review Delivery | Guidelines and Instruments Used | Review Level |
|--------|-----------------------|----------------------------|------------------------|-----------------------------------------------|-----------------|--------------------------------|-------------|
| Lepler et al,35 1993 | 12 People with intellectual disability, community | Psychotropic drugs | Nurse, psychologist, care staff, physician | Yes; family or advocate | Multidisciplinary review every 3 mo of clinical presentation, medication response, and adverse effects, laboratory monitoring, alternative interventions, and other factors leading to drug recommendations based on team consensus; final decisions are a combination of team recommendations, patient and family preference, and physician opinion | No formal guidelines or standard instruments used in this medication review | 3 |
| Ferguson et al,31 1982 | 97 People with intellectual disability, institution | Antipsychotic drugs | Physician, psychologist, social worker, nurse, pharmacist, care staff | No | Monthly multidisciplinary review of target symptoms and medication adverse effects with data (counts of challenging behavior) used to direct drug dose changes according to a specified protocol | No formal guidelines or standard instruments used in this medication review | 2 |
| Inoue, 33 1982 | 251 People with intellectual disability, institution | Psychotropic drugs | Pharmacist, physician, nurse, care staff | No | Monthly pharmacist collected data on patient condition, response to treatment, drug adverse effects presented at multidisciplinary meetings; pharmacist recommendations for treatment discussed and accepted or declined | Standard data forms used to inform reviews | 2 |
| Ellenor et al,30 1977 | 208 People with intellectual disability, institution | Psychotropic drugs | Physician, pharmacist, nurse, psychologist, sociologist, therapist | No | Pharmacist collected data every 3 mo on drug history, interactions, adverse effects, clinical presentation, response to treatment, and made recommendations that were discussed and accepted or declined at multidisciplinary meetings | Data collected on a standard form | 2 |

#### Electronic Identification of Prescribing Followed by Clinician Medication Review

| Source | Participants, Setting | Psychotropic Drugs | Professionals Involved | Patient or Patient Representative Involvement | Review Delivery | Guidelines and Instruments Used | Review Level |
|--------|-----------------------|-------------------|------------------------|-----------------------------------------------|-----------------|--------------------------------|-------------|
| Donat,46 2006 | People with mental illness, hospital | Psychotropic drugs (as-needed use) | Psychiatrist, psychologist | No | Automated identification of patients receiving as-needed medication ≥3 times a week followed by case review by psychiatrist and psychologist using a semistructured form to guide decisions; further review by a senior management committee in some cases | Local guidelines | 2 |
| Seltzer et al,49 2000 | Adults and children, community | Sedatives and hypnotics | Physician | NR | Automated identification of patients prescribed long-term or high-dose sedatives or intraclass polypharmacy followed by letter to prescriber to prompt review of medication (this stage of medication review not well described) | No formal guidelines or standard instruments used in this medication review | 1 |
| Craig et al,47 1984 | People with mental illness, hospital | Psychotropic drugs | Physician | No | Automated identification of patients receiving high or low drug doses or polypharmacy followed by clinical review by 2 physicians to judge appropriateness of prescribing; further review by senior physicians when agreement not reached | No formal guidelines or standard instruments used in this medication review | 2 |
| Laska et al,48 1980 | People with mental illness, hospital | Psychotropic drugs | Physicians | No | Automated identification of patients receiving high or low drug doses or polypharmacy followed by drug review by 2 physicians and consultation with a peer group, if necessary | No formal guidelines or standard instruments used in this medication review | 2 |

Abbreviations: CD, cannot determine; NICE, National Institute for Health and Care Excellence; NR, not reported. a No. of participants not given.
Medication-Related Outcomes of Psychotropic Medication Review

A measure of change in psychotropic drug prescribing after focused psychotropic medication review was the most consistently reported medication-related outcome. Ballard et al,23 Jordan et al,26 and Patterson et al27 report a significant effect of focused psychotropic medication review in reducing psychotropic drug prescribing in cognitively impaired elderly residents of nursing homes (pooled odds ratio, 0.24; 95% CI, 0.14-0.39) (Figure 2).23,25-27 Additional data obtained from Moncrieff et al25 showed a nonsignificant tendency to greater change in antipsychotic medication among adults with severe mental illness undergoing outpatient focused psychotropic medication review conducted by their usual psychiatrist than among those receiving standard care (odds ratio, 0.38; 95% CI, 0.12-1.19).

One-off focused psychotropic medication review was associated with mean of 34.0% (95% CI, 32.9%-35.2%) of participants having a change in medication prescription (Figure 3A).29,37,38,40,41,43-45,49 Four before-after studies report the effect of focused medication review on antipsychotic drugs prescribed for behavioral and psychological symptoms of dementia.37,38,40,41 These reviews, conducted by either a pharmacist37,38,41 or general practitioner,40 were associated with a reduction or discontinuation of antipsychotic drugs in 20% to 61% of participants.

Gemelli et al43 investigated pharmacist review of sedative and hypnotic medication in elderly people living in a nursing home. The intervention was associated with dose reduction or discontinuation in 49% of the sample by follow-up at 3 months.

Two before-after studies addressed the effect on drug prescribing of clinical review of long-term antidepressant drug therapy in community-dwelling adults. One large Scottish study (N = 2849) found that 28.5% of individuals taking antidepressants had a medication change after in-person review by their general practitioner, with most changes being drug discontinuation or dose reduction.44 A similar study, conducted on a much smaller scale (N = 32), reported that medication change followed just above half of the medication reviews conducted by a specialist nurse prescriber.45

The 4 studies that used electronic prescribing records to identify prescribing that fell outside defined guidelines to generate alerts, prompting clinician-focused psychotropic medication review, all report that the process was associated with improved rates of guideline-compliant prescribing.46-49

Several studies report the association of a program of multidisciplinary medication review with psychotropic prescribing. In all but 1 case, these studies were conducted before 2000 and focused on the use of psychotropic drugs for challenging behavior in adults with intellectual disability, most of whom were receiving long-term institutional care.28-36 The quality of these studies is poor to fair, yet together they report results of psychotropic medication review of a relatively homogeneous group of more than 1000 adults (most with severe to profound intellectual disability and behavior disturbance living in large institutional facilities), with follow-up of between 6 months and 4 years.

Figure 2. Forest Plot Showing Odds of Change in Antipsychotic Medication and Odds of Reduction in Psychotropic Medication Following Focused Medication Review vs Treatment as Usual

| Source | Change in psychotropic medication | Reduction in psychotropic medication |
|--------|----------------------------------|--------------------------------------|
| Moncrieff et al,25 2016 | 60 | 0.38 (0.12-1.19) |
| Ballard et al,23 2016 | 277 | 0.17 (0.05-0.60) |
| Jordan et al,26 2015 | 43 | 0.22 (0.06-0.87) |
| Patterson et al,27 2010 | 334 | 0.26 (0.14-0.49) |
| Overall effect: $I^2 = 0.0%$; $P = .83$ | | 0.24 (0.14-0.39) |

The size of the data markers is determined by weight from random-effects analysis. OR indicates odds ratio.
Figure 3B28,31-35 shows the proportion of participants in these studies undergoing a reduction or change in psychotropic medication after the review programs, where this metric is given or can be extrapolated from the published results (mean proportion changing prescription, 57.6%; 95% CI, 53.2%-62.0%). These studies demonstrate the association of focused psychotropic medication review with medication change in a potentially overmedicated group; most changes were dose reductions or discontinuations.

Studies that do not report the proportion of participants with medication change still report an association with either reduction of overall psychotropic prescribing at the group level30,36 or reduced rates of polypharmacy.28,34 Ellenor and Frisk30 demonstrate a reduction of 37% in psychotropic prescription items during the course of a 2-year regular medication review and Marcoux36 found that their process of psychotropic medication review was associated with a mean dose reduction of 17% in individuals receiving antipsychotic drugs. An exception to these findings is a more recent study by Dahl et al,39 who report the results of a thorough multidisciplinary psychotropic review in people with dementia who lived in nursing homes. The review was associated with minimal change in prescribing of any class of psychotropic drug, although interpretation is limited by movement of participants into and out of the intervention group.

Psychotropic polypharmacy among participants before and after the medication review program was reported by 3 studies.28,30,34 All 3 studies report a substantial reduction in the total volume of psychotropics associated with focused psychotropic medication review.
Clinical and Patient-Related Outcomes of Psychotropic Medication Review

Several disparate clinical outcomes were measured in twelve studies (Table 2).23-30,32-34 Ballard et al23 reported significantly more neuropsychiatric symptoms at 9-month follow-up in people with dementia receiving antipsychotic review compared with controls (group difference in Neuropsychiatric Inventory score, 7.37; 95% CI, 1.53-13.22). Furthermore, people receiving the intervention demonstrated a nominal worsening in health-related quality of life (measured with the DEMQOL: Dementia Quality of Life measure), which did not reach statistical significance (group difference, 4.54; 95% CI, -9.26 to 0.19).24 There was no difference in agitation, depression, or mortality between groups.

The medication review intervention tested by Moncrieff et al25 was co-designed with people with severe mental illness with the aim of increasing patient involvement and agency in decision making regarding antipsychotics. There was no difference in scores on the Decision Self-Efficacy Scale between those randomized to receive the intervention and those receiving treatment as usual, suggesting that the focused psychotropic medication review did not improve patients’ confidence in discussions or decisions about psychotropic medication. Those in the review group demonstrated a tendency to greater medication adherence but no significant difference was found in other secondary outcome measures of patient satisfaction, attitude toward psychotropic drugs, symptoms of psychosis, or adverse effects of antipsychotic drugs between groups at follow-up 2 to 4 weeks after the review meeting. However, fidelity of implementation was poor and the study tested only feasibility and therefore was not powered to detect effect sizes.

Jordan et al26 reported that more medication-related problems were identified and addressed with nurse-led medication review than without. There was no significant difference in change in psychopathologic characteristics of dementia, behavior changes, or functional ability between groups during the study period. Longer-term outcomes on patient health or well-being were not assessed.

Patterson et al27 measured the rate of falls in a group of individuals with dementia who needed a high level of care. The reductions in inappropriate psychotropic drug use in the intervention group vs the control group did not translate to a difference in the rate of falls between groups (11.4 falls per 100 person-months in the control group vs 16.3 falls per 100 person-months in intervention group; \(P = .09\)), although the method of recording falls was subject to inaccuracies and the authors note that the study was underpowered.

Gallimore et al42 reviewed the potential for a focused psychotropic medication review by a remote pharmacist, conducted several weeks after out-patient psychiatry consultation, to improve rates of routine adverse drug event monitoring. The focused psychotropic medication review was associated with an increase in the proportion of participants with up-to-date laboratory monitoring and significantly reduced the proportion of those at risk of drug-drug interactions but had no effect on the proportion of participants who were monitored for movement adverse effects. The actual benefit in terms of adverse drug event rates was not measured.

The study by Bisconer et al28 was the only one, to our knowledge, to report rates of adverse drug events, albeit with a basic and unvalidated method. The proportion of the cohort with any physician-observed adverse effect decreased from 14% at baseline to 10% after the review program, but the small number of participants is a major limitation of this study.

Four studies report change in challenging behavior as a result of antipsychotic review and reduction programs in institutions for people with intellectual disability.28,30,32,34 These studies report a decrease or no change in challenging behavior associated with the delivery of the program. The authors concluded that many psychotropic drugs given in this population can be stopped without causing further deterioration in behavior.
| Source | Clinical Outcome Measure | Result |
|--------|--------------------------|--------|
| Ballard et al, 2016 | Neuropsychiatric symptoms | Difference between intervention and control groups favors control: 7.37 (95% CI, 1.53-13.22; P = .03) |
| Ballard et al, 2017 | Agitation | Difference between intervention and control groups: 4.60 (95% CI, −1.43 to 10.63; P = .13) |
| Moncrieff et al, 2016 | Depression | Difference between intervention and control groups: −1.70 (95% CI, −4.29 to 0.89; P = .19) |
| Jordan et al, 2015 | Drug-related problems addressed (adverse effects) | Difference between intervention and control groups favors intervention: 3.34 (95% CI, 2.57-4.11; P < .001) |
| Gallimore et al, 2016 | Up-to-date laboratory monitoring | Proportion of participants | 54.1% (before); 72.1% (after) (P < .001) |
| Jordan et al, 2015 | Attitude toward medication | Difference between intervention and control groups: 1.65 (95% CI, −0.49 to 3.80; P = .19) |
| Brachard, 1996 | Clinical presentation | Proportion of participants | 75% (before); 63% (after) (P = .21) |
| Bisconer et al, 1995 | Challenging behavior | Difference between intervention and control groups: −0.42 (95% CI, −8.12 to 7.29) |
| Glaser et al, 1986 | Aggressive challenging behavior | Mean decrease in challenging behavior after intervention | No significant difference between intervention and control groupb |
| Inoue, 1982 | Clinical presentation | Proportion of participants | 96.5% (114/118) receiving intervention, 3.5% (4/114) not receiving intervention |
|  |  | Proportion of participants | 14% (16/114) receiving intervention, 86% (98/114) not receiving intervention |

Abbreviation: OR, odds ratio.

a Results statistically significant at P < .05.

b These studies had control groups only for the secondary outcome of change in challenging behavior.

These studies had control groups only for the secondary outcome of change in challenging behavior.
**Economic Outcomes of Psychotropic Medication Review**

Five studies[^26] reported descriptive cost data in terms of savings made after focused psychotropic medication review. None of the 5 studies conducted comprehensive economic evaluation (eTable 3 in the Supplement).

**Discussion**

Psychotropic medication plays a central role in the treatment of mental disorders, yet remains the subject of debate. Treatment benefits must be balanced against adverse drug events, which are both common and distressing.[^50] Rising rates of prescription of psychotropic drugs are observed worldwide, despite the modest effect size of these medications for most indications[^51] and the increasing availability of and evidence for nonpharmacologic interventions. From an economic perspective, the estimated US annual expenditure on psychotropic drugs of $30 billion[^52] must be viewed in the context of nonadherence rates of up to 65%,[^53] which contributes to significant waste of health care resources. On a personal level, patient views and preferences should be respected, but many report feeling disempowered and excluded from decisions about psychotropic medication.[^54]

Medication optimization aims to address these tensions through a variety of strategies, including medication review.

Our review of the literature shows that programs of focused psychotropic medication review have attracted ongoing interest and have been instituted across different settings during the past 4 decades. There is considerable diversity in how focused psychotropic medication review has been delivered.

Meta-analysis of 3 RCTs demonstrated a significantly greater likelihood of psychotropic drug reduction with focused psychotropic medication review than with treatment as usual in elderly individuals with dementia living in nursing homes.[^23][^26][^27] Results from several uncontrolled before-after studies seem to support this finding by reporting an association between medication review and change in drug prescribing, irrespective of participant group. This finding indicates potential for improved prescribing after medication review and, although it seems logical that a change in medication after a critical evaluation will be beneficial, the clinical gains after focused psychotropic medication review cannot be assumed. Many studies did not measure benefits (or harms) associated with medication review. A change in drug prescribing is an intermediary outcome that offers only a crude measure of medication optimization; only 1 study objectively assessed medication appropriateness against consensus guidelines.[^27] One RCT reported identification of a greater number of adverse drug events as a result of focused psychotropic medication review, but not the resolution of these adverse events.[^26] Two RCTs failed to demonstrate any benefit of medication review on clinically meaningful parameters[^25][^27] and 1 RCT reported deterioration in patients' neuropsychiatric symptoms after medication review and subsequent reduction in drug prescribing.[^23][^24]

The medication optimization approach is intrinsically patient-centric[^55] and medication review can provide an opportunity to explore patient beliefs and preferences and to reach shared treatment decisions. However, with 1 notable exception,[^25] our review highlights a major lack of patient input and personalization in existing focused psychotropic medication reviews, which represents a significant barrier to achieving true medication optimization. This finding may reflect the age of several of the studies and a prevailing paternalism in medication decision making in those prescribed psychotropic drugs.[^56]

The potential for financial savings is a strong motivator for medication optimization, yet investigation of the economic implications and resource use of psychotropic medication review has largely been neglected. Any cost savings from reductions in prescribing and avoidance of adverse drug events must be offset against the initial outlay of performing the medication review, additional activity generated (eg, referrals to another health care professional or increased monitoring mandated by drug changes), and switches to more expensive drugs or preparations. In these terms,
our findings support calls for more attention to be paid to economic evaluation of medication review.57,58

Most of the studies included in our review were conducted in elderly individuals, people with dementia, or adults with intellectual disability, in many cases residing in institutional facilities. People in these groups are at high risk of suboptimal psychotropic use and overuse and may lack the capacity to consent to treatment decisions, yet their underrepresentation in controlled clinical trials leads to a lack of empirical evidence and data-driven prescribing guidelines. Individual regular and pragmatic psychotropic medication review may have the most to offer to these groups, where advantages of medications are less well established and adverse effects are common and idiosyncratic. However, to realize this potential, the quality and reproducibility of future studies must be improved. Although recent studies are more robust methodologically, the overall risk of bias is high, with limitations conferred by both study design and reporting. Future trials should ensure standardized reporting of the intervention (eg, using the TIDieR [Template for Intervention Description and Replication] checklist59) and address the feasibility and acceptability of medication review interventions, as their implementation in routine care may be complex25 and they may not always be welcomed by patients or their caregivers.60 Moreover, inconsistencies in terminology should be resolved and the concept of medication review clearly delineated from other attempts to optimize psychotropic prescribing.61,62

Data in the included studies were not sufficiently detailed to enable subgroup analysis of medication reviews, beyond grouping interventions by one-off medication review and ongoing review programs. Multidisciplinary review programs, conducted mostly with participants with intellectual disability living in institutional care, tended to be associated with the greatest proportion of participants changing medication, although this finding could be a function of the high level of psychotropic use in this group.63

There is no universally accepted standard procedure for medication review.16,64,65 Although best practice advice and consolidated tools have been developed to guide medication review66,67 and define potentially inappropriate prescribing,68-70 few of the medication reviews were informed by a theoretical model. There is the potential for electronic mechanisms, including e-prescribing and the electronic patient record, to support medication review, in a way which does not yet seem to have been investigated fully.71

Our findings do not suggest a professional discipline that should lead psychotropic medication review, although third-party reviews by a professional (usually a pharmacist) external to the usual team might be difficult to embed in routine care. As few as one-third of medication recommendations made by pharmacists are actioned by prescribers,37 and nonprescribers conducting reviews often report lacking influence,72 highlighting the importance of good interprofessional communication in complex medication review interventions.

Existing studies and reviews that evaluate the effect of medication review (in other populations and focused on other drug types) similarly conclude that medication review can influence proximal medication-related outcomes but demonstrate weak evidence of benefit in clinical and patient outcomes.56,67,73,74 Despite this finding, medication review is recommended by guidelines as part of routine care for several groups at high risk of suboptimal prescribing and adverse drug events, including elderly individuals, those with chronic conditions, and those receiving polypharmacy.16,75

This systematic review and meta-analysis was of focused psychotropic medication review. As an isolated intervention, focused medication review has limitations. Comprehensive medication review, in which all medications are reviewed simultaneously regardless of indication, can highlight drug-drug interactions that might be missed by focusing on psychotropics alone. In practice, however, psychotropic drug prescribing is often performed by specialists who may not feel equipped to review medication for physical health conditions. A treatment review that also incorporates response to nonpharmacologic interventions is attractive, but might be difficult to protocolize where treatment aims span different dimensions.
Strengths and Limitations

To our knowledge, this is the first systematic review to synthesize the evidence for focused psychotropic medication review. We applied few limits to the search and included varied study designs. We identified several additional articles through hand searches; this approach is likely to reflect the nebulous nature of the intervention and a lack of consistent terminology, as well as poor indexing of older studies. Members of the research team independently appraised studies against prespecified inclusion criteria and judged study quality using published frameworks. We conducted meta-analysis and calculated pooled effects where possible.

The deficits of the primary literature limit the strength of our conclusions about the benefits of psychotropic medication review. Most studies included were uncontrolled and prone to bias and confounding, and it is difficult to attribute causality in before-after designs. It is impossible to blind participants and practitioners to the intervention, although blinding might not be essential where outcomes (eg, prescribing rates) are objective. Clinical outcomes of medication review may only become apparent after some time; thus, the limited follow-up in the included studies is a major problem. Diversity in outcome measures and reporting precluded more extensive meta-analysis. There is potential for publication bias to skew the results of this review and there were insufficient data to assess this risk statistically. We did not search the gray literature.

Conclusions

Focused psychotropic medication review as a structured and critical evaluation of a patient’s drug therapy has the potential to contribute to medication optimization. Despite much attention and incorporation into routine care, the evidence for focused psychotropic medication review as a standalone intervention is weak and it has not been shown that changes in psychotropic prescribing associated with focused psychotropic medication review translate to improved clinical and patient-important outcomes. High-quality research is essential before a routine program of focused psychotropic medication review can be recommended, either in general or special populations. Standardization of nomenclature, processes, and an agreed common set of outcomes that prioritizes patient-important measures is needed. This might be achieved with the creation of a national or international collaborative medication review research network.

ARTICLE INFORMATION

Accepted for Publication: August 21, 2018.
Published: October 26, 2018. doi:10.1001/jamanetworkopen.2018.3750

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2018 Sheehan R et al. JAMA Network Open.

Corresponding Author: Rory Sheehan, MSc, Division of Psychiatry, University College London, 149 Tottenham Court Rd, Sixth Floor, Maple House, London W1T 7NF, United Kingdom (r.sheehan@ucl.ac.uk).

Author Affiliations: Division of Psychiatry, University College London, London, United Kingdom (Sheehan, Brown, Hassiotis); Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom (Strydom); Department of Primary Care and Population Health, University College London, London, United Kingdom (Marston).

Author Contributions: Dr Sheehan had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Sheehan, Strydom, Marston, Hassiotis.

Acquisition, analysis, or interpretation of data: Sheehan, Brown, Marston, Hassiotis.

Drafting of the manuscript: Sheehan, Brown, Hassiotis.

Critical revision of the manuscript for important intellectual content: Sheehan, Strydom, Marston, Hassiotis.

Statistical analysis: Sheehan, Marston.

Obtained funding: Sheehan, Strydom, Marston.
Administrative, technical, or material support: Brown, Hassiotis.

Supervision: Strydom, Marston, Hassiotis.

Conflict of Interest Disclosures: None reported.

Funding/Support: Dr Sheehan is funded by National Institute for Health Research Doctoral Research Fellowship DRF-2016-09-140.

Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: This report is independent research supported by the National Institute for Health Research (NIHR Doctoral Research Fellowship, Dr Rory Sheehan, DRF-2016-09-140). The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health.

REFERENCES

1. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66(8):848-856. doi:10.1001/archgenpsychiatry.2009.81

2. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177-184. doi:10.1002/pds.2082

3. Stephenson CP, Karanges E, McGregor IS. Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. Aust N Z J Psychiatry. 2013;47(1):74-87. doi:10.1177/0004867412466595

4. Moore TJ, Mattison DR. Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Intern Med. 2017;177(2):274-275. doi:10.1001/jamainternmed.2016.7507

5. Ndukwe HC, Tordoff JM, Wang T, Nisthal PS. Psychotropic medicine utilization in older people in New Zealand from 2005 to 2013. Drugs Aging. 2014;31(10):755-768. doi:10.1007/s40266-014-0205-1

6. Maust DT, Langa KM, Blow FC, Kales HC. Psychotropic use and associated neuropsychiatric symptoms among patients with dementia in the USA. Int J Geriatr Psychiatry. 2017;32(2):164-174. doi:10.1002/gps.4452

7. Olfson M, King M, Schoenbaum M. Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry. 2015;72(9):867-874. doi:10.1001/jamapsychiatry.2015.0500

8. Park SY, Cervesi C, Galling B, et al. Antipsychotic use trends in youth with autism spectrum disorder and/or intellectual disability: a meta-analysis. J Am Acad Child Adolesc Psychiatry. 2016;55(6):456-468. doi:10.1016/j.jaac.2016.03.012

9. Sheehan R, Hassiotis A, Walters K, Osborn D, Strydom A, Horsfall L. Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ. 2015;351:h4326. doi:10.1136/bmj.h4326

10. Lunskey Y, Khoo W, Tadrous M, Vigod S, Cobigo V, Gomes T. Antipsychotic use with and without comorbid psychiatric diagnosis among adults with intellectual and developmental disabilities. Can J Psychiatry. 2018;63(6):361-369. doi:10.1177/07067437177727240

11. Hampton LM, Daubresse M, Chang H-Y, Alexander GC, Budnitz DS. Emergency department visits by adults for psychiatric medication adverse events. JAMA Psychiatry. 2014;71(9):1006-1014. doi:10.1001/jamapsychiatry.2014.436

12. Moncrieff J, Cohen D, Porter S. The psychoactive effects of psychiatric medication: the elephant in the room. J Psychoactive Drugs. 2013;45(5):409-415. doi:10.1080/02791072.2013.845328

13. Ilyas S, Moncrieff J. Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. Br J Psychiatry. 2012;200(5):393-398. doi:10.1192/bjp.bp.111.104257

14. Hodgson D, Thomas CP, O'Brien PL, et al. Projected spending on psychotropic medications 2013-2020. Adm Policy Ment Health. 2016;43(4):497-505. doi:10.1007/s10488-015-0661-x

15. Bulloch AG, Patten SB. Non-adherence with psychotropic medications in the general population. Soc Psychiatry Psychiatr Epidemiol. 2010;45(1):47-56. doi:10.1007/s00127-009-0041-5

16. National Institute for Health and Care Excellence. Medicines Optimisation: the Safe and Effective Use of Medicines to Enable the Best Possible Outcomes. London, UK: National Institute for Health and Care Excellence; 2015.
17. Maust DT, Kim HM, Chiang C, Kales HC. Association of the Centers for Medicare & Medicaid Services’ National Partnership to Improve Dementia Care with the use of antipsychotics and other psychotropic drugs in long-term care in the United States from 2009 to 2014. JAMA Intern Med. 2018;178(5):640-647. doi:10.1001/jamainternmed.2018.0379

18. UK National Prescribing Centre. Room for Review: A Guide to Medication Review: The Agenda for Patients, Practitioners and Managers. London, UK: Medicines Partnership; 2002.

19. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2018. https://www.whocc.no/atc_ddd_index/. Accessed August 10, 2018.

20. National Heart, Lung, and Blood Institute. Study quality assessment tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed August 10, 2018.

21. StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP; 2015.

22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. doi:10.1136/bmj.327.7414.557

23. Ballard C, Orrell M, YongZhong S, et al. Impact of antipsychotic review and nonpharmacological intervention on antipsychotic use, neuropsychiatric symptoms, and mortality in people with dementia living in nursing homes: a factorial cluster-randomized controlled trial by the Well-Being and Health for People With Dementia (WHELD) program. Am J Psychiatry. 2016;173(3):252-262. doi:10.1176/appi.ajp.2015.15010130

24. Ballard C, Orrell M, Sun Y, et al. Impact of antipsychotic review and non-pharmacological intervention on health-related quality of life in people with dementia living in care homes: WHELD—a factorial cluster randomised controlled trial. Int J Geriatr Psychiatry. 2017;32(10):1094-1103. doi:10.1002/gps.4572

25. Moncrieff J, Azam K, Johnson S, et al. Results of a pilot cluster randomised trial of the use of a medication review tool for people taking antipsychotic medication. BMC Psychiatry. 2016;16:205. doi:10.1186/s12888-016-0921-7

26. Jordan S, Gabe-Walters ME, Watkins A, et al. Nurse-led medicines’ monitoring for patients with mental illness living in care homes: a pragmatic cohort stepped wedge cluster randomised trial. PLoS One. 2015;10(10):e0140203. doi:10.1371/journal.pone.0140203

27. Patterson SM, Hughes CM, Crealey G, Cardwell C, Lapane KL. An evaluation of an adapted US model of pharmaceutical care to improve psychoactive prescribing for nursing home residents in Northern Ireland (Fleetwood Northern Ireland Study). J Am Geriatr Soc. 2010;58(1):44-53. doi:10.1111/j.1532-5415.2009.02617.x

28. Bisconer SW, Zhang X, Sine LF. Impact of a psychotropic medication and physical restraint review process on adults with mental retardation, psychiatric diagnoses, and challenging behaviors. J Dev Phys Disabil. 1995;7(2):123-135. doi:10.1007/BF02684957

29. Branford D. A review of antipsychotic drugs prescribed for people with learning disabilities who live in Leicester. J Intellect Disabil Res. 1996;40(pt 4):358-368. doi:10.1111/j.1365-2788.1996.tb00641.x

30. Ellenor GL, Frisk PA. Pharmacist impact on drug use in an institution for the mentally retarded. Am J Hosp Pharm. 1977;34(6):604-608.

31. Ferguson DG, Cullari S, Davidson NA, Breuning SE. Effects of data-based interdisciplinary medication reviews on the prevalence and pattern of neuroleptic drug use with institutionalized mentally retarded persons. Educ Train Ment Retard. 1982;17(2):103-108.

32. Glaser BA, Morreau LE. Effects of interdisciplinary team review on the use of antipsychotic agents with severely and profoundly mentally retarded patients. Am J Ment Defic. 1986;90(4):371-379.

33. Ionue F. A clinical pharmacy service to reduce psychotropic medication use in an institution for mentally handicapped persons. Ment Retard. 1982;20(2):70-74.

34. Jauernig R, Hudson A. Evaluation of an interdisciplinary review committee managing the use of psychotropic medication with people with intellectual disabilities. J Intellect Dev Disabil. 1995;20(1):51-61.

35. Lepler S, Hodas A, Cotter-Mack A. Implementation of an interdisciplinary psychotropic drug review process for community-based facilities. Ment Retard. 1993;31(5):307-315.

36. Marcoux AW. Implementation of a psychotropic drug review service in a mental retardation facility. Hosp Pharm. 1985;20(11):827-831.

37. Bach LL, Lazzaretto DL, Young CF, Lofholm PW. Improving nursing home compliance via revised antipsychotic use survey tool. Consult Pharm. 2017;32(4):228-238. doi:10.4140/TCP.n.2017.228

38. Child A, Clarke A, Fox C, Maidment I. A pharmacy led program to review anti-psychotic prescribing for people with dementia. BMC Psychiatry. 2012;12:155. doi:10.1186/1711-2444-12-155
39. Dahl LJ, Wright R, Xiao A, Keeven A, Carr DB. Quality improvement in long term care: the Psychotropic Assessment Tool (PAT). J Am Med Dir Assoc. 2008;9(9):676-683. doi:10.1016/j.jamda.2008.07.002

40. Morrison A. Antipsychotic prescribing in nursing homes: an audit report. Qual Prim Care. 2009;17(5):359-362.

41. Prentice A, Wright D. Reducing antipsychotic drugs in care homes. Nurs Times. 2014;110(23):12-15.

42. Gallimore CE, Sokhal D, Zeidler Schreiter E, Margolis AR. Pharmacist medication reviews to improve safety monitoring in primary care patients. Fam Syst Health. 2016;34(2):104-113. doi:10.1037/fsy0000185

43. Gemelli MG, Yockel K, Hohmeier KC. Evaluating the impact of pharmacist on reducing use of sedative/hypnotics for treatment of insomnia in long-term care facility residents. Consult Pharm. 2016;31(11):650-657. doi:10.4140/TCPhn.2016.650

44. Johnson CF, Macdonald HJ, Atkinson P, Buchanan AI, Downes N, Dougall N. Reviewing long-term antidepressants can reduce drug burden: a prospective observational cohort study. Br J Gen Pract. 2012;62(604):e773-e779. doi:10.3399/bjgp12X658304

45. Napolitano J, Hirst C, Oldknow H. Review clinic for people receiving antidepressants. Ment Health Pract. 2012;16(4):10. doi:10.7748/mhp2012.12.16.4.10.c9465

46. Donat DC. Impact of a clinical-administrative review procedure on reducing reliance on psychotropic PRN medication. Psychiatr Rehabil J. 2006;29(3):215-218. doi:10.2975/29.2006.215.218

47. Craig TJ, Mehta RM. Clinician-computer interaction: automated review of psychotropic drugs. Am J Psychiatry. 1984;141(2):267-270. doi:10.1176/ajp.141.2.267

48. Lasky E, Siegel C, Simpson G. Automated review system for orders of psychotropic drugs. Arch Gen Psychiatry. 1980;37(7):824-827. doi:10.1001/archpsyc.1980.01780200102013

49. Seltzer JK, Kurt TL, Knodel LC, Dean B, Burch C. Texas Medicaid Vendor Drug Program Drug Utilization Review Board. Drug utilization review of sedative/hypnotic agents in Texas Medicaid patients. J Am Pharm Assoc (Wash). 2000;40(4):495-499.

50. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617-622.

51. Seemüller F, Möller H-J, Dittmann S, Musil R. Is the efficacy of psychopharmacological drugs comparable to the efficacy of general medicine medication? BMC Med. 2012;10:17. doi:10.1186/1741-7015-10-17

52. Greenblatt DJ, Harnatz JS, Shider RI. Update on psychotropic drug prescribing in the United States: 2014-2015. J Clin Psychopharmacol. 2016;38(1):1-4. doi:10.1097/JCP.0000000000000892

53. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497. doi:10.1056/NEJMra050100

54. Morant N, Azam K, Johnson S, Moncrieff J. The least worst option: user experiences of antipsychotic medication and lack of involvement in medication decisions in a UK community sample. J Ment Health. 2017;31:1-7. doi:10.1080/09638237.2017.1370637

55. Royal Pharmaceutical Society. Medicines Optimisation: Helping Patients to Make the Most of Medicines. London, UK: Royal Pharmaceutical Society; 2013.

56. Goss C, Moretti F, Mazzi MA, Del Piccolo L, Rimondini M, Zimmermann C. Involving patients in decisions during psychiatric consultations. Br J Psychiatry. 2008;193(5):416-421. doi:10.1192/bjp.bp.107.048728

57. Faria R, Barbieri M, Light K, Elliott RA, Sculpher M. The economics of medicines optimization: policy developments, remaining challenges and research priorities. Br Med Bull. 2014;111(1):45-61. doi:10.1093/bmb/ldu021

58. Hasan SS, Thiruchelvam K, Kow CS, Ghorì MU, Babar Z-U-D. Economic evaluation of pharmacist-led medication reviews in residential aged care facilities. Expert Rev Pharmacoecon Outcomes Res. 2017;17(5):431-439. doi:10.1080/14737714.2017.1370376

59. Hoffmann TC, Glasziou PP, Bouton I, et al. Better reporting of interventions: Template for Intervention Description and Replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. doi:10.1136/bmj.g1687

60. Petty DR, Knapp P, Raynor DK, House AO. Patients' views of a pharmacist-run medication review clinic in general practice. Br J Gen Pract. 2003;53(493):607-613.

61. Rose AJ, Fischer SH, Paasche-Orlow MK. Beyond medicine reconciliation: the correct medication list. JAMA. 2017;317(20):2057-2058. doi:10.1001/jama.2017.4628

62. Zimmerman KM, Salgado TM, Dixon DL. Medication reconciliation vs medication review. JAMA. 2017;318(10):965-966. doi:10.1001/jama.2017.0552

63. Matson JL, Bamburg JW, Mayville EA, et al. Psychopharmacology and mental retardation: a 10 year review (1990-1999). Res Dev Disabil. 2000;21(4):263-296. doi:10.1016/S0891-4222(00)00042-1
